Labcorp announces launch of Labcorp Plasma Detect

Labcorp announced the launch of Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA molecular residual disease solution in early stage colon cancer to identify patients at increased risk of recurrence after surgery or adjuvant chemotherapy. This solution, which is designed for research use but also suitable for clinical applications, can be applied across solid tumors with a scalable and standardized approach to facilitate faster turnaround times while maintaining high analytical performance.